Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully ...
On Tuesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $ ...
Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.
Lantheus will acquire Evergreen Theragnostics for $250 million upfront, plus up to $752.5 million in milestone payments, closing in H2 2025. The Life Molecular Imaging acquisition adds Neuraceq to ...
Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront. As part of the deal, which was announced ...
Lantheus ( (LNTH)) has shared an update. On January 27, 2025, Lantheus Medical Imaging, a subsidiary of Lantheus Holdings, announced an agreement to acquire Evergreen Theragnostics for $250 ...
Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of $250M and up to an additional $752.5M in ...
Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Evergreen Theragnostics. For its new asset, Lantheus will make an ...